The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Oral Vaccine for Human Market Research Report 2024
Synopsis
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.
Global Oral Vaccine for Human market is projected to reach US$ 3746.5 million in 2029, increasing from US$ 2540 million in 2022, with the CAGR of 5.7% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oral Vaccine for Human market research.
The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Oral Vaccine for Human market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other
Segment by Application
Public
Private
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Oral Vaccine for Human report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Orally administered vaccines are of interest, as they elicit both systemic and mucosal immunities, in which mucosal immunity would neutralize the mucosa invading pathogen before the onset of an infection.
Global Oral Vaccine for Human market is projected to reach US$ 3746.5 million in 2029, increasing from US$ 2540 million in 2022, with the CAGR of 5.7% during the period of 2023 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Oral Vaccine for Human market research.
The oral vaccine market is driven by the growing demand for convenient and needle-free vaccination options, especially in pediatric and developing regions. Oral vaccines offer advantages like ease of administration, increased patient compliance, and simplified logistics, making them suitable for mass vaccination programs and reaching remote areas with limited healthcare infrastructure. The potential for improved vaccine stability and reduced production costs further contribute to market growth. However, the market also faces challenges, such as the need for enhanced vaccine stability to withstand gastrointestinal conditions and ensuring consistent efficacy across diverse populations. Additionally, regulatory complexities and the requirement for stringent safety and efficacy data can pose obstacles for oral vaccine manufacturers. To succeed in this market, companies must focus on innovative vaccine delivery technologies, conduct robust clinical trials, collaborate with global health agencies, and address public perception and trust in oral vaccine safety and effectiveness.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Oral Vaccine for Human market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Merck
GSK
Sanofi
Lanzhou Institute
Serum Institute
Valneva
Shanghai United Cell
Bibcol
PaxVax
Vabiotech
Tiantan Biological
EuBiologics
Panacea Biotec Ltd
Bio-Med
Halfkin Bio-Pharmaceuticals
Segment by Type
Rotavirus Vaccine
Cholera Vaccine
Oral Polio Vaccine
Other
Segment by Application
Public
Private
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Oral Vaccine for Human report covers below items:
Chapter 1: Product Basic Information (Definition, Type and Application)
Chapter 2: Manufacturers’ Competition Patterns
Chapter 3: Country Level Sales Analysis
Chapter 4: Product Type Analysis
Chapter 5: Product Application Analysis
Chapter 6: Manufacturers’ Outline
Chapter 7: Industry Chain, Market Channel and Customer Analysis
Chapter 8: Market Opportunities and Challenges
Chapter 9: Market Conclusions
Chapter 10: Research Methodology and Data Source
Index1 Oral Vaccine for Human Market Overview
1.1 Product Overview and Scope of Oral Vaccine for Human
1.2 Oral Vaccine for Human Segment by Type
1.2.1 Global Oral Vaccine for Human Market Value Comparison by Type (2023-2029)
1.2.2 Rotavirus Vaccine
1.2.3 Cholera Vaccine
1.2.4 Oral Polio Vaccine
1.2.5 Other
1.3 Oral Vaccine for Human Segment by Application
1.3.1 Global Oral Vaccine for Human Market Value by Application: (2023-2029)
1.3.2 Public
1.3.3 Private
1.4 Global Oral Vaccine for Human Market Size Estimates and Forecasts
1.4.1 Global Oral Vaccine for Human Revenue 2018-2029
1.4.2 Global Oral Vaccine for Human Sales 2018-2029
1.4.3 Global Oral Vaccine for Human Market Average Price (2018-2029)
1.5 Assumptions and Limitations
2 Oral Vaccine for Human Market Competition by Manufacturers
2.1 Global Oral Vaccine for Human Sales Market Share by Manufacturers (2018-2023)
2.2 Global Oral Vaccine for Human Revenue Market Share by Manufacturers (2018-2023)
2.3 Global Oral Vaccine for Human Average Price by Manufacturers (2018-2023)
2.4 Global Oral Vaccine for Human Industry Ranking 2021 VS 2022 VS 2023
2.5 Global Key Manufacturers of Oral Vaccine for Human, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Oral Vaccine for Human, Product Type & Application
2.7 Oral Vaccine for Human Market Competitive Situation and Trends
2.7.1 Oral Vaccine for Human Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Oral Vaccine for Human Players Market Share by Revenue
2.7.3 Global Oral Vaccine for Human Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Oral Vaccine for Human Retrospective Market Scenario by Region
3.1 Global Oral Vaccine for Human Market Size by Region: 2018 Versus 2022 Versus 2029
3.2 Global Oral Vaccine for Human Global Oral Vaccine for Human Sales by Region: 2018-2029
3.2.1 Global Oral Vaccine for Human Sales by Region: 2018-2023
3.2.2 Global Oral Vaccine for Human Sales by Region: 2024-2029
3.3 Global Oral Vaccine for Human Global Oral Vaccine for Human Revenue by Region: 2018-2029
3.3.1 Global Oral Vaccine for Human Revenue by Region: 2018-2023
3.3.2 Global Oral Vaccine for Human Revenue by Region: 2024-2029
3.4 North America Oral Vaccine for Human Market Facts & Figures by Country
3.4.1 North America Oral Vaccine for Human Market Size by Country: 2018 VS 2022 VS 2029
3.4.2 North America Oral Vaccine for Human Sales by Country (2018-2029)
3.4.3 North America Oral Vaccine for Human Revenue by Country (2018-2029)
3.4.4 United States
3.4.5 Canada
3.5 Europe Oral Vaccine for Human Market Facts & Figures by Country
3.5.1 Europe Oral Vaccine for Human Market Size by Country: 2018 VS 2022 VS 2029
3.5.2 Europe Oral Vaccine for Human Sales by Country (2018-2029)
3.5.3 Europe Oral Vaccine for Human Revenue by Country (2018-2029)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Oral Vaccine for Human Market Facts & Figures by Country
3.6.1 Asia Pacific Oral Vaccine for Human Market Size by Country: 2018 VS 2022 VS 2029
3.6.2 Asia Pacific Oral Vaccine for Human Sales by Country (2018-2029)
3.6.3 Asia Pacific Oral Vaccine for Human Revenue by Country (2018-2029)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Oral Vaccine for Human Market Facts & Figures by Country
3.7.1 Latin America Oral Vaccine for Human Market Size by Country: 2018 VS 2022 VS 2029
3.7.2 Latin America Oral Vaccine for Human Sales by Country (2018-2029)
3.7.3 Latin America Oral Vaccine for Human Revenue by Country (2018-2029)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Oral Vaccine for Human Market Facts & Figures by Country
3.8.1 Middle East and Africa Oral Vaccine for Human Market Size by Country: 2018 VS 2022 VS 2029
3.8.2 Middle East and Africa Oral Vaccine for Human Sales by Country (2018-2029)
3.8.3 Middle East and Africa Oral Vaccine for Human Revenue by Country (2018-2029)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Oral Vaccine for Human Sales by Type (2018-2029)
4.1.1 Global Oral Vaccine for Human Sales by Type (2018-2023)
4.1.2 Global Oral Vaccine for Human Sales by Type (2024-2029)
4.1.3 Global Oral Vaccine for Human Sales Market Share by Type (2018-2029)
4.2 Global Oral Vaccine for Human Revenue by Type (2018-2029)
4.2.1 Global Oral Vaccine for Human Revenue by Type (2018-2023)
4.2.2 Global Oral Vaccine for Human Revenue by Type (2024-2029)
4.2.3 Global Oral Vaccine for Human Revenue Market Share by Type (2018-2029)
4.3 Global Oral Vaccine for Human Price by Type (2018-2029)
5 Segment by Application
5.1 Global Oral Vaccine for Human Sales by Application (2018-2029)
5.1.1 Global Oral Vaccine for Human Sales by Application (2018-2023)
5.1.2 Global Oral Vaccine for Human Sales by Application (2024-2029)
5.1.3 Global Oral Vaccine for Human Sales Market Share by Application (2018-2029)
5.2 Global Oral Vaccine for Human Revenue by Application (2018-2029)
5.2.1 Global Oral Vaccine for Human Revenue by Application (2018-2023)
5.2.2 Global Oral Vaccine for Human Revenue by Application (2024-2029)
5.2.3 Global Oral Vaccine for Human Revenue Market Share by Application (2018-2029)
5.3 Global Oral Vaccine for Human Price by Application (2018-2029)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.1.4 Merck Oral Vaccine for Human Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 GSK
6.2.1 GSK Corporation Information
6.2.2 GSK Description and Business Overview
6.2.3 GSK Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.2.4 GSK Oral Vaccine for Human Product Portfolio
6.2.5 GSK Recent Developments/Updates
6.3 Sanofi
6.3.1 Sanofi Corporation Information
6.3.2 Sanofi Description and Business Overview
6.3.3 Sanofi Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.3.4 Sanofi Oral Vaccine for Human Product Portfolio
6.3.5 Sanofi Recent Developments/Updates
6.4 Lanzhou Institute
6.4.1 Lanzhou Institute Corporation Information
6.4.2 Lanzhou Institute Description and Business Overview
6.4.3 Lanzhou Institute Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Lanzhou Institute Oral Vaccine for Human Product Portfolio
6.4.5 Lanzhou Institute Recent Developments/Updates
6.5 Serum Institute
6.5.1 Serum Institute Corporation Information
6.5.2 Serum Institute Description and Business Overview
6.5.3 Serum Institute Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.5.4 Serum Institute Oral Vaccine for Human Product Portfolio
6.5.5 Serum Institute Recent Developments/Updates
6.6 Valneva
6.6.1 Valneva Corporation Information
6.6.2 Valneva Description and Business Overview
6.6.3 Valneva Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.6.4 Valneva Oral Vaccine for Human Product Portfolio
6.6.5 Valneva Recent Developments/Updates
6.7 Shanghai United Cell
6.6.1 Shanghai United Cell Corporation Information
6.6.2 Shanghai United Cell Description and Business Overview
6.6.3 Shanghai United Cell Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.4.4 Shanghai United Cell Oral Vaccine for Human Product Portfolio
6.7.5 Shanghai United Cell Recent Developments/Updates
6.8 Bibcol
6.8.1 Bibcol Corporation Information
6.8.2 Bibcol Description and Business Overview
6.8.3 Bibcol Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.8.4 Bibcol Oral Vaccine for Human Product Portfolio
6.8.5 Bibcol Recent Developments/Updates
6.9 PaxVax
6.9.1 PaxVax Corporation Information
6.9.2 PaxVax Description and Business Overview
6.9.3 PaxVax Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.9.4 PaxVax Oral Vaccine for Human Product Portfolio
6.9.5 PaxVax Recent Developments/Updates
6.10 Vabiotech
6.10.1 Vabiotech Corporation Information
6.10.2 Vabiotech Description and Business Overview
6.10.3 Vabiotech Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.10.4 Vabiotech Oral Vaccine for Human Product Portfolio
6.10.5 Vabiotech Recent Developments/Updates
6.11 Tiantan Biological
6.11.1 Tiantan Biological Corporation Information
6.11.2 Tiantan Biological Oral Vaccine for Human Description and Business Overview
6.11.3 Tiantan Biological Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.11.4 Tiantan Biological Oral Vaccine for Human Product Portfolio
6.11.5 Tiantan Biological Recent Developments/Updates
6.12 EuBiologics
6.12.1 EuBiologics Corporation Information
6.12.2 EuBiologics Oral Vaccine for Human Description and Business Overview
6.12.3 EuBiologics Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.12.4 EuBiologics Oral Vaccine for Human Product Portfolio
6.12.5 EuBiologics Recent Developments/Updates
6.13 Panacea Biotec Ltd
6.13.1 Panacea Biotec Ltd Corporation Information
6.13.2 Panacea Biotec Ltd Oral Vaccine for Human Description and Business Overview
6.13.3 Panacea Biotec Ltd Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.13.4 Panacea Biotec Ltd Oral Vaccine for Human Product Portfolio
6.13.5 Panacea Biotec Ltd Recent Developments/Updates
6.14 Bio-Med
6.14.1 Bio-Med Corporation Information
6.14.2 Bio-Med Oral Vaccine for Human Description and Business Overview
6.14.3 Bio-Med Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.14.4 Bio-Med Oral Vaccine for Human Product Portfolio
6.14.5 Bio-Med Recent Developments/Updates
6.15 Halfkin Bio-Pharmaceuticals
6.15.1 Halfkin Bio-Pharmaceuticals Corporation Information
6.15.2 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Description and Business Overview
6.15.3 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Sales, Revenue and Gross Margin (2018-2023)
6.15.4 Halfkin Bio-Pharmaceuticals Oral Vaccine for Human Product Portfolio
6.15.5 Halfkin Bio-Pharmaceuticals Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Oral Vaccine for Human Industry Chain Analysis
7.2 Oral Vaccine for Human Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Oral Vaccine for Human Production Mode & Process
7.4 Oral Vaccine for Human Sales and Marketing
7.4.1 Oral Vaccine for Human Sales Channels
7.4.2 Oral Vaccine for Human Distributors
7.5 Oral Vaccine for Human Customers
8 Oral Vaccine for Human Market Dynamics
8.1 Oral Vaccine for Human Industry Trends
8.2 Oral Vaccine for Human Market Drivers
8.3 Oral Vaccine for Human Market Challenges
8.4 Oral Vaccine for Human Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
